SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001140361-24-022708
Filing Date
2024-04-29
Accepted
2024-04-29 08:30:24
Documents
16
Period of Report
2023-12-31

Document Format Files

Seq Description Document Type Size
1 10-K/A ef20027445_10ka.htm   iXBRL 10-K/A 433715
2 EXHIBIT 31.3 ef20027445_ex31-3.htm EX-31.3 5742
3 EXHIBIT 31.4 ef20027445_ex31-4.htm EX-31.4 6128
  Complete submission text file 0001140361-24-022708.txt   701543

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA apri-20231231.xsd EX-101.SCH 4200
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE apri-20231231_def.xml EX-101.DEF 1918
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE apri-20231231_lab.xml EX-101.LAB 32051
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE apri-20231231_pre.xml EX-101.PRE 23125
20 EXTRACTED XBRL INSTANCE DOCUMENT ef20027445_10ka_htm.xml XML 7302
Mailing Address 300 PARK AVENUE 2ND FLOOR NEW YORK NY 10022
Business Address 300 PARK AVENUE 2ND FLOOR NEW YORK NY 10022 (646) 293-2100
SEELOS THERAPEUTICS, INC. (Filer) CIK: 0001017491 (see all company filings)

IRS No.: 870449967 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 000-22245 | Film No.: 24886744
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)